São Paulo - Delayed Quote BRL

GSK plc (G1SK34.SA)

Compare
40.94
0.00
(0.00%)
At close: January 28 at 12:44:16 PM GMT-3
Loading Chart for G1SK34.SA
DELL
  • Previous Close 40.94
  • Open 0.00
  • Bid 40.84 x --
  • Ask 42.00 x --
  • Day's Range 0.00 - 0.00
  • 52 Week Range 0.00 - 50.15
  • Volume 0
  • Avg. Volume 165
  • Market Cap (intraday) 417.641B
  • Beta (5Y Monthly) 0.33
  • PE Ratio (TTM) 23.13
  • EPS (TTM) 1.77
  • Earnings Date Feb 5, 2025
  • Forward Dividend & Yield 1.80 (4.40%)
  • Ex-Dividend Date Nov 13, 2024
  • 1y Target Est --

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.

www.gsk.com

70,212

Full Time Employees

December 31

Fiscal Year Ends

Recent News: G1SK34.SA

View More

Performance Overview: G1SK34.SA

Trailing total returns as of 1/30/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

G1SK34.SA
1.49%
FTSE 100
5.50%

1-Year Return

G1SK34.SA
10.32%
FTSE 100
12.25%

3-Year Return

G1SK34.SA
23.99%
FTSE 100
14.75%

5-Year Return

G1SK34.SA
20.79%
FTSE 100
14.48%

Compare To: G1SK34.SA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: G1SK34.SA

View More

Valuation Measures

Annual
As of 1/29/2025
  • Market Cap

    416.50B

  • Enterprise Value

    510.13B

  • Trailing P/E

    23.14

  • Forward P/E

    8.12

  • PEG Ratio (5yr expected)

    0.80

  • Price/Sales (ttm)

    1.85

  • Price/Book (mrq)

    4.09

  • Enterprise Value/Revenue

    2.24

  • Enterprise Value/EBITDA

    10.44

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    8.02%

  • Return on Assets (ttm)

    7.24%

  • Return on Equity (ttm)

    21.85%

  • Revenue (ttm)

    31.31B

  • Net Income Avi to Common (ttm)

    2.51B

  • Diluted EPS (ttm)

    1.77

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.21B

  • Total Debt/Equity (mrq)

    119.37%

  • Levered Free Cash Flow (ttm)

    6.04B

Research Analysis: G1SK34.SA

View More

Company Insights: G1SK34.SA

Research Reports: G1SK34.SA

View More

People Also Watch